Approximately 20–40% of pediatric patients with anaplastic large-cell lymphoma (ALCL) develop recurrent disease. Here, we report a pilot experience using single-drug weekly vinorelbine (25 mg/m2/wk) as a salvage re-induction regimen in 4 consecutive pediatric patients with relapsed ALCL. All 4 patients achieved complete remission after 2 cycles of weekly vinorelbine and were disease-free alive at last evaluation. The main toxicity was hematologic. Only one week of vinorelbine administration was withheld for a grade 4 neutropenia in one patient. The results suggest that weekly vinorelbine has good efficacy and safety in the treatment of relapsed pediatric ALCL.